<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372709</url>
  </required_header>
  <id_info>
    <org_study_id>771-0008</org_study_id>
    <nct_id>NCT01372709</nct_id>
  </id_info>
  <brief_title>TriVascular Post-Market Registry</brief_title>
  <official_title>A Post-Market Study to Evaluate the Safety and Performance of the Ovation™ or Ovation Prime™ Abdominal Stent Graft System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriVascular, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriVascular, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational post-market study of subjects receiving the Ovation™ or
      Ovation Prime™ Abdominal Stent Graft System (&quot;Ovation™ or Ovation Prime™ Abdominal Stent
      Graft System Post-Market Study&quot;) in the treatment of abdominal aortic aneurysms (AAA). The
      Ovation™ or Ovation Prime™ Abdominal Stent Graft System Post-Market study is intended to
      expand the clinical knowledge base by collecting data on subjects treated with the Ovation™
      or Ovation Prime™ Abdominal Stent Graft System in actual clinical practice following
      commercial approval.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success at 12 Months Post-Implantation/surgery.</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary endpoint is treatment success at 12 months post-implantation/surgery. Treatment success is defined as a composite technical endpoint composed of successful introduction and deployment of the Ovation™ or Ovation Prime™ Abdominal Stent Graft System at the initial implantation procedure along with clinical endpoints of absence from type I or III endoleaks, aneurysm expansion, aneurysm rupture, conversion to open surgical repair, graft migration, and graft occlusion at 12 months post-implantation procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Performance Endpoints</measure>
    <time_frame>1, 6, &amp;12 Months</time_frame>
    <description>Freedom from type I and III endoleaks [1 &amp; 6 m, &amp; annual through 5 years]
Freedom from aneurysm rupture [6 m, &amp; annual through 5 years]
Freedom from aneurysm related mortality [1 month]
Freedom from aneurysm expansion [6 m, &amp; annual through 5 years]
Freedom from stent graft migration [6 m, &amp; annual through 5 years]
Freedom from loss of device patency [1 &amp; 6 m, &amp; annual through 5 years]
Freedom from aneurysm-related secondary endovascular procedures [1 &amp; 6 m, &amp; annual through 5 years]
Freedom from device related adverse events [1 &amp; 6 m, &amp; annual through 5 years]</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">501</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Ovation™ or Ovation Prime™ Abdominal Stent Graft System</arm_group_label>
    <description>Adult male and female patients will be consecutively screened for the study. Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ovation™ or Ovation Prime™ Abdominal Stent Graft System</intervention_name>
    <description>Single occurrence permanent implant of AAA device.</description>
    <arm_group_label>Ovation™ or Ovation Prime™ Abdominal Stent Graft System</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Ovation™ or Ovation Prime™ Abdominal Stent Graft System study is a multicenter,
        prospective, observational post-market study of subjects receiving the Ovation™ or Ovation
        Prime™ Abdominal Stent Graft System for the treatment of abdominal aortic aneurysms (AAA).
        The Ovation™ or Ovation Prime™ Abdominal Stent Graft System Post-Market Study intends to
        expand the clinical evidence of the safety and performance of the Ovation™ or Ovation
        Prime™ Abdominal Stent Graft System in an all comers (&quot;real world&quot;) patient population.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is &gt; 18 years or minimum age as required by local regulations.

          -  Indication for elective repair of AAA with an endovascular stent graft in accordance
             with the Instructions for Use of the Ovation™ or Ovation Prime™ Abdominal Stent Graft
             System.

          -  Subject has signed an Ethics Committee (EC) approved Informed Consent Form. The
             subject or legal representative has been informed of the nature of the study, has
             consented to participate, and has authorized the collection and release of his/her
             medical information.

          -  Subject intends to electively receive the Ovation™ or Ovation Prime™ Abdominal Stent
             Graft System.

          -  Subject has the ability and willingness to comply with all follow-up exams as
             indicated in clinical investigation plan.

        Exclusion Criteria:

          -  Subject demonstrates high probability of non-adherence to physician's follow-up
             requirements.

          -  Subject's current participation in a concurrent randomized control trial (RCT) or
             investigational device/drug study which could confound study results.

          -  Life expectancy less than 1 year

          -  Pregnancy

          -  Subjects with poor renal function as indicated by a serum creatinine &gt; 2.5mg/dl.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Park Hospital Leipzig</name>
      <address>
        <city>Strümpellstr. 41</city>
        <state>Leipzig</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.trivascular.com/</url>
    <description>TriVascular Website</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abdominal</keyword>
  <keyword>aortic</keyword>
  <keyword>aneurysm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

